Clinacin 150mg Tablets for Dogs

Država: Irska

Jezik: angleščina

Source: HPRA (Health Products Regulatory Authority)

Aktivna sestavina:

Clindamycin (as clindamycin hydrochloride)

Dostopno od:

Chanelle Animal Health Ltd.

Koda artikla:

QJ01FF01

INN (mednarodno ime):

Clindamycin (as clindamycin hydrochloride)

Odmerek:

150 mg/tablet

Farmacevtska oblika:

Tablet

Tip zastaranja:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapevtska skupina:

Dogs

Terapevtsko območje:

clindamycin

Terapevtske indikacije:

Antibacterial

Status dovoljenje:

Authorised

Datum dovoljenje:

1999-11-26

Lastnosti izdelka

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clinacin 150mg Tablets for Dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE: Clindamycin 150 mg (as clindamycin hydrochloride)
EXCIPIENT:
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
An oblong white tablet, with a break-line on one side.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of:-
Infected wounds, abscesses and oral cavity/dental infections caused by
or associated with clindamycin-sensitive species of;
•
_Staphylococcus_ spp.
•
_Streptococcus_ spp.
•
_Bacteroides_ spp.
•
_Fusobacterium necrophorum_
•
_Clostridium perfringens_
Osteomyelitis
•
_Staphylococcus aureus_
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to clindamycin or
lincomycin.
Do not administer to rabbits,
hamsters,
guinea pigs,
chinchillas,
horses or ruminants because ingestion of clindamycin by these
species may result in severe gastro-intestinal disturbance.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_8_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_4_
_9_
_3_
_7_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged therapy of one month or greater, periodic liver and
kidney function tests and